The Crystalline Nephropathies

Overview

Journal Kidney Int Rep

Publisher Elsevier

Specialty Nephrology

Date 2021 Dec 13

PMID 34901567

Citations 24

Authors

Mark A Perazella

Leal C Herlitz

Affiliations

Soon will be listed here.

Abstract

Crystalline nephropathies are a unique form of kidney disease characterized by the histologic finding of intrarenal crystal deposition. The intrinsic nature of some molecules and ions combined with a favorable tubular fluid physiology leads to crystal precipitation and deposition within the tubular lumens. Crystal deposition promotes kidney injury through tubular obstruction and both direct and indirect cytotoxicities. Further kidney injury develops from inflammation triggered by these crystals. From a clinical standpoint, the crystalline nephropathies are associated with abnormal urinalysis and urinary sediment findings, tubulopathies, acute kidney injury (AKI), and/or chronic kidney disease (CKD). Urine sediment examination is often helpful in alerting clinicians to the possibility of crystal-related kidney injury. The identification of crystals within the kidneys on biopsy by pathologists prompts clinicians to evaluate patients for medication-related kidney injury, dysproteinemia-related malignancies, and certain inherited disorders. This review will focus on the clinical and pathologic aspects of these 3 categories of crystalline nephropathies.

Citing Articles

Acute toxicity effects of ethylene glycol on lethal dose 50 (LD), urine production, and histopathology change renal tubule cell in mice.

Meles D, Mustofa I, Wurlina W, Donova C, Hidayanti E, Suwasanti N Open Vet J. 2025; 14(12):3539-3551.

PMID: 39927377 PMC: 11799633. DOI: 10.5455/OVJ.2024.v14.i12.36.

Methotrexate Crystals on Electron Microscopy of Kidney Biopsy for Acute Kidney Injury.

Fang D, Poznanski N, Arend L Kidney Med. 2024; 6(12):100924.

PMID: 39634329 PMC: 11615596. DOI: 10.1016/j.xkme.2024.100924.

An updated approach to the evaluation of the urinary sediment.

Fogazzi G, Garigali G, Abinti M, Lieti G, Verdesca S Pediatr Nephrol. 2024; 40(4):933-945.

PMID: 39377940 DOI: 10.1007/s00467-024-06545-9.

Tubulointerstitial nephritis in children and adolescents.

Gurevich E, Landau D Pediatr Nephrol. 2024; 40(2):319-328.

PMID: 39320551 DOI: 10.1007/s00467-024-06526-y.

Severe acute kidney injury due to oxalate crystal induced severe interstitial nephritis: A case report.

Lathiya M, Errabelli P, Roy S, Mareedu N World J Nephrol. 2024; 13(2):93976.

PMID: 38983760 PMC: 11229832. DOI: 10.5527/wjn.v13.i2.93976.

References

Runolfsdottir H, Palsson R, Agustsdottir I, Indridason O, Edvardsson V . Kidney Disease in Adenine Phosphoribosyltransferase Deficiency. Am J Kidney Dis. 2016; 67(3):431-8. PMC: 4819988. DOI: 10.1053/j.ajkd.2015.10.023. View

Ball P, Tillotson G . Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf. 1995; 13(6):343-58. DOI: 10.2165/00002018-199513060-00004. View

Veys K, Elmonem M, Van Dyck M, Janssen M, Cornelissen E, Hohenfellner K . Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis. J Am Soc Nephrol. 2020; 31(5):1092-1106. PMC: 7217422. DOI: 10.1681/ASN.2019080774. View

Green M, Chamberlain M . Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol. 2008; 63(4):599-604. DOI: 10.1007/s00280-008-0772-0. View

Liebow A, Li X, Racie T, Hettinger J, Bettencourt B, Najafian N . An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol. 2016; 28(2):494-503. PMC: 5280024. DOI: 10.1681/ASN.2016030338. View

Scott L, Keam S . Lumasiran: First Approval. Drugs. 2021; 81(2):277-282. DOI: 10.1007/s40265-020-01463-0. View

Nishijima T, Tsuchiya K, Tanaka N, Joya A, Hamada Y, Mizushima D . Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. J Antimicrob Chemother. 2014; 69(12):3320-8. DOI: 10.1093/jac/dku304. View

Servais A, Moriniere V, Grunfeld J, Noel L, Goujon J, Chadefaux-Vekemans B . Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping. Clin J Am Soc Nephrol. 2008; 3(1):27-35. PMC: 2390982. DOI: 10.2215/CJN.01740407. View

Perazella M . Pharmacology behind Common Drug Nephrotoxicities. Clin J Am Soc Nephrol. 2018; 13(12):1897-1908. PMC: 6302342. DOI: 10.2215/CJN.00150118. View

10.

Le Dudal M, Huguet L, Perez J, Vandermeersch S, Bouderlique E, Tang E . Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning. J Clin Invest. 2019; 129(6):2571-2577. PMC: 6538379. DOI: 10.1172/JCI99822. View

11.

Medrano C, Oberic L, Puisset F, Recher C, Larrieu-Ciron D, Ysebaert L . Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients. Leuk Lymphoma. 2020; 62(4):846-853. DOI: 10.1080/10428194.2020.1846733. View

12.

Chopra N, Fine P, Price B, Atlas I . Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol. 2000; 164(2):438. View

13.

Martin-Higueras C, Ludwig-Portugall I, Hoppe B, Kurts C . Targeting kidney inflammation as a new therapy for primary hyperoxaluria?. Nephrol Dial Transplant. 2018; 34(6):908-914. DOI: 10.1093/ndt/gfy239. View

14.

Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G . Ciprofloxacin crystal nephropathy. Am J Kidney Dis. 2007; 50(2):330-5. DOI: 10.1053/j.ajkd.2007.05.014. View

15.

Gupta V, El Ters M, Kashani K, Leung N, Nasr S . Crystalglobulin-induced nephropathy. J Am Soc Nephrol. 2014; 26(3):525-9. PMC: 4341488. DOI: 10.1681/ASN.2014050509. View

16.

Perazella M . Crystal-induced acute renal failure. Am J Med. 1999; 106(4):459-65. DOI: 10.1016/s0002-9343(99)00041-8. View

17.

DCosta M, Dalvin L, Manohar S, Maguire L, Grande J, Gonsalves W . Crystalglobulin-Induced Nephropathy and Keratopathy. Kidney Med. 2020; 1(2):71-74. PMC: 7380400. DOI: 10.1016/j.xkme.2019.01.006. View

18.

Strauss S, Waltuch T, Bivin W, Kaskel F, Levin T . Primary hyperoxaluria: spectrum of clinical and imaging findings. Pediatr Radiol. 2016; 47(1):96-103. DOI: 10.1007/s00247-016-3723-7. View

19.

Simon D, Brosius 3rd F, Rothstein D . Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990; 150(11):2379-84. DOI: 10.1001/archinte.150.11.2379. View

20.

Mulay S, Evan A, Anders H . Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant. 2013; 29(3):507-14. DOI: 10.1093/ndt/gft248. View